Introduction Patients with preeclampsia (PE) exhibit different serum concentrations of sFlt-1
and PlGF. The sFlt-1/PlGF ratio can be used as an aid in the diagnosis of preeclampsia …

Abstract Aims: The sFlt-1/PlGF ratio has been evaluated as a diagnostic marker for
preeclampsia (PE). The aim of this study was to explore the use of the sFlt-1/PlGF ratio as an …

Introduction Severe preeclampsia is associated with characteristic changes of sFlt-1 and
PlGF levels in the maternal serum. Objectives The aim of our study is the determination of …

Introduction The sFlt-1/PlGF ratio has emerged as a biomarker for the timely diagnosis of
preeclampsia and prediction of pregnancy outcomes. In most reports the ratio has been …

Abstract Objective: The sFlt-1/PlGF ratio is a valid marker in diagnosing or excluding
preeclampsia. The currently used cut offs frame an intermediate zone of 33–85 (< 34 0 …

Objective: Hypertensive disorders of pregnancy such as preeclampsia (PE) remain a
leading cause of maternal and fetal morbidity and mortality. The prediction of the course of …

Preeclampsia is associated with significant morbidity and mortality for mother and baby.
Although around 30% of all pregnancies are evaluated for preeclampsia, diagnosis is …

Objective To evaluate the additive value of the sFlt-1/PlGF ratio for diagnosing preeclampsia
(PE) and predicting prolongation of pregnancy and adverse outcome in a cohort of women …

Background and Objectives: Preeclampsia is a health issue characterized by a new onset of
hypertension after 20 weeks of gestation and proteinuria. This is a multiple organ disorder …

Background Management of pregnant women at high risk of pre-eclampsia (PE) requires
frequent monitoring, with referral to specialized perinatal care centers. Reliable tests are …